At 105-156 weeks, data were available from only three trials, one each for liraglutide (Le Roux 2017), orlistat (Torgerson 2004), and semaglutide (Lincoff 2023), reporting placebo-subtracted TBWL of 4.2%, 3.0%, and 8.7%, respectively
Starting body composition plays a major role, with individuals carrying higher body fat percentages often experiencing more dramatic absolute changes, while leaner individuals may see slower but steady improvements in stubborn fat areas
Medvis longevity and scale give it operational credibility that newer entrants lack
The information available on our Direct Peptides website: is provided for educational purposes only
The exception was intended to help a small subset of patients who are unable to take an FDA-approved product for a legitimate medical reason, like an allergy to a preservative or inactive ingredient